Related Experiment Videos
[Goals and practical implementation of lipid therapy in coronary heart disease]
1Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg.
Insights
Managing coronary heart disease involves assessing lipid profiles to classify hyperlipidemias. Treatment aims to lower LDL cholesterol, and triglycerides, while increasing HDL cholesterol through diet or medication.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Context:
- Coronary heart disease (CHD) management necessitates comprehensive lipid profiling.
- Hyperlipidemia classification is crucial for targeted treatment strategies.
Purpose:
- To outline the diagnostic and therapeutic approach for lipid management in CHD patients.
- To define target lipid levels and effective intervention strategies.
Summary:
- Fasting lipid profiles (total cholesterol, LDL, HDL, triglycerides) are essential for CHD patients.
- Hyperlipidemias are classified based on elevated LDL cholesterol and/or triglycerides.
- Treatment goals include LDL cholesterol < 100 mg/dl, HDL cholesterol > 35 mg/dl, and triglycerides < 200 mg/dl.
- Interventions involve dietary changes and lipid-lowering medications like HMG-CoA reductase inhibitors, bile acid sequestrants, fibrates, or nicotinic acid.
Impact:
- Establishes clear lipid management goals for CHD patients.
- Provides a framework for selecting appropriate pharmacotherapies based on lipid profiles.
- Aims to reduce cardiovascular risk through effective lipid control.
Abstract:
In all patients with coronary heart disease a fasting lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) should be obtained. Hyperlipidemias can then be classified as hypercholesterolemia (LDL cholesterol elevated), mixed hyperlipidemia (LDL cholesterol elevated, triglycerides elevated) and hypertriglyceridemia (triglycerides elevated). Primary goal of lipid intervention is a LDL cholesterol < 100 mg/dl, secondary goals are HDL cholesterol > 35 mg/dl and triglycerides < 200 mg/dl. These goals can be reached by dietary intervention alone (reduction in fat and modification of fat intake) or in combination with lipid lowering drugs. Monotherapy with HMG-CoA reductase inhibitors or combined therapy with bile acid sequestrants will allow a reduction in LDL cholesterol by more than 50%; in predominant hypertriglyceridemia fibrates or nicotinic acid will lower triglycerides and elevate HDL cholesterol.